Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349322 · ClinicalTrials.gov registry record · Phase 3
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
A Phase 3 study of Breast Cancer, sponsored by Radiation Therapy Oncology Group.
- Active
- Registry status
- Phase 3
- Development phase
- 2,354
- Enrollment target
- 20
- Study locations
NCT01349322 is a Phase 3 study of Breast Cancer that is active but no longer recruiting, run by Radiation Therapy Oncology Group. The registered enrollment target is 2,354 participants, below the 2,801-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (16% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT01349322, a Phase 3 study of Breast Cancer, is active but no longer recruiting, sponsored by Radiation Therapy Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,354 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: It is not yet know whether higher per daily radiation therapy is equally as effective as standard per daily radiation therapy in treating breast cancer. PURPOSE: This randomized phase III trial studies how well an accelerated course of higher per daily radiation therapy with concomitant boost works compared to standard per daily radiation therapy with a sequential boost in treating patients with early-stage breast cancer that was removed by surgery.
Conditions Studied
Interventions
- RADIATION Standard fractionation whole breast irradiation
- RADIATION Hypofractionated whole breast irradiation
- RADIATION Concurrent boost
- RADIATION Sequential boost
Study Locations (20)
California
- Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park - Cameron Park
- Mercy San Juan Medical Center - Carmichael
- Enloe Medical Center - Chico
- City of Hope Comprehensive Cancer Center - Duarte
- Epic Care-Dublin - Dublin
- 21st Century Oncology - El Segundo - El Segundo
- UC San Diego Moores Cancer Center - La Jolla
- Los Angeles County-USC Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Arizona
- 21st Century Oncology-Scottsdale - Scottsdale
- Mayo Clinic in Arizona - Scottsdale
- Arizona Oncology Associates-West Orange Grove - Tucson
- Banner University Medical Center - Tucson - Tucson
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
- The Kirklin Clinic at Acton Road - Birmingham
Arkansas
- CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,354 participants |
| Start Date | 2011-05-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01349322
The ClinicalTrials.gov registry entry for NCT01349322 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 2,354 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,801-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (16% lower). The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Standard fractionation whole breast irradiation is the first listed.
NCT01349322 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT01349322 about?
NCT01349322 is a clinical study titled "Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery". RATIONALE: It is not yet know whether higher per daily radiation therapy is equally as effective as standard per daily radiation therapy in treating breast cancer. PURPOSE: This randomized phase III trial studies how well an accelerated course of higher per daily radiation therapy with concomitant ...
What is the current status of trial NCT01349322?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 2,354 participants. The study started on 2011-05-24.
What conditions does trial NCT01349322 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT01349322?
The interventions under investigation include: Standard fractionation whole breast irradiation (RADIATION), Hypofractionated whole breast irradiation (RADIATION), Concurrent boost (RADIATION), Sequential boost (RADIATION).
Who is sponsoring clinical trial NCT01349322?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01349322 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.